Quanta Announces The Appointment Of Vanessa L. Jacoby As The New Chief Business Offer & Chief Financial Offer And Reports Progress Across Its Clinical Programs

Quanta Therapeutics, a privately held clinical-stage biopharmaceutical company focused on developing oral therapies for RAS-driven cancers, has announced the appointment of Vanessa L. Jacoby as its new Chief Business Officer and Chief Financial Officer. Ms. Jacoby brings over 25 years of experience in financial strategy and leadership within the biopharmaceutical industry.

In addition to this leadership appointment, the company has also begun enrollment in the dose expansion phase of its ongoing Phase 1 clinical trial evaluating QTX3034, a G12D-selective multi-KRAS inhibitor. The trial is assessing QTX3034 both as a standalone treatment and in combination with cetuximab in patients with solid tumors carrying KRASG12D mutations. The decision to move into dose expansion is based on favorable safety outcomes and promising early signs of efficacy from the dose escalation portion of the study.

Perry Nisen, MD, PhD, Chief Executive Officer of Quanta, stated, “We are excited to welcome Ms. Jacoby to the executive team to support our next phase of development and growth as a clinical-stage company. Ms. Jacoby has extensive financial and business development leadership experience in both public and private biotech companies, including establishing financial strategy, building operational frameworks, and helping shape corporate direction.”

Dr. Nisen mentioned, “Additionally, the opening of dose expansion cohorts in the Phase 1 clinical trial of QTX3034 is an important milestone for the program and company, signifying early positive safety and anti-tumor activity as a monotherapy and in combination. We look forward to progressing the program and presenting data at a major medical meeting later this year.”

Ms. Jacoby also added, “I am delighted to be joining Quanta at this pivotal stage of development as the company continues to advance novel small molecule cancer medicines targeting previously undruggable KRAS mutations with the potential to address the most prevalent drivers of cancer. I look forward to partnering with the team to support the advancement of our pipeline and build a strong financial foundation for future growth.”

Ms. Jacoby joins Quanta from Shoreline Biosciences, where she served as Chief Financial Officer. During her time there, she was instrumental in securing a $140 million Series B financing round and establishing high-value partnerships with Kite Pharma and BeiGene, together totaling $3.7 billion in potential deal value. Before that, she was Chief Accounting Officer at Avidity Biosciences, where she led corporate finance efforts and supported both the company’s initial public offering and crossover financing.

Earlier in her career, Ms. Jacoby held various leadership roles at PharmAkea (acquired by Galecto), Brain Cells, Artes Medical, and Verenium. She began her career as an auditor at Ernst & Young. She holds a B.S. in Business Administration from Fundação Armando Alvares Penteado in São Paulo, Brazil, and is a Certified Public Accountant in the State of California (inactive status). With the addition of Ms. Jacoby to the executive team and continued progress in the clinical development of QTX3034, Quanta Therapeutics is advancing its mission to deliver innovative treatment options for patients with RAS-mutated cancers.